Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis

Based on extensive pre-clinical studies, the oncolytic parvovirus H-1 (H-1PV) is currently applied to patients with recurrent glioblastoma in a phase I/IIa clinical trial (ParvOryx01, NCT01301430). Cure rates of about 40% in pediatric high-risk medulloblastoma (MB) patients also indicate the need of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacroix, Jeannine, Schlund, Franziska, Leuchs, Barbara, Adolph, Kathrin, Sturm, Dominik, Bender, Sebastian, Hielscher, Thomas, Pfister, Stefan M, Witt, Olaf, Rommelaere, Jean, Schlehofer, Jörg R, Witt, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Cancer Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232887/
https://www.ncbi.nlm.nih.gov/pubmed/23852775
http://dx.doi.org/10.1002/ijc.28386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232887/
https://www.ncbi.nlm.nih.gov/pubmed/23852775
http://dx.doi.org/10.1002/ijc.28386

Ejemplares similares